Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
While all these stocks have registered negative returns in last one month, a few have declined significantly since the beginning of 2023. For instance, while Beam Therapeutics and Ginkgo Bioworks lost over 21% this year, Verve Therapeutics stock declined over 29% in the period.Cathie Wood-led ARK Investment Management raised stakes in a number of biotech companies on Wednesday with these stocks recording negative returns over the last one month, potentially making them attractive in terms of valuations.
凱西·伍德-領導 方舟投資管理 週三在多家生物科技公司的股份上升，這些股票在過去一個月錄得負回報，這些股票在估值方面具有吸引力。
What Happened: Funds operated by ARK bought shares of $CRISPR Therapeutics (CRSP.US)$, $Intellia Therapeutics (NTLA.US)$, $Verve Therapeutics (VERV.US)$, $Beam Therapeutics (BEAM.US)$ and $Ginkgo Bioworks (DNA.US)$.
The purchase was conducted via the flagship $ARK Innovation ETF (ARKK.US)$ and the $ARK Genomic Revolution ETF (ARKG.US)$. ARK's funds are estimated to have shelled out a cumulative $2 million for the purchase of these five stocks on Wednesday, according to valuations based on the day's closing price.
購買是通過旗艦進行的 $ARK Innovation ETF (ARKK.US)$ 和 $ARK生物基因科技革新主動型ETF (ARKG.US)$。根據當天收盤價的估值，ARK 的資金估計將在周三進行購買這五隻股票的累計抵銷 200 萬美元。
While all these stocks have registered negative returns in last one month, a few have declined significantly since the beginning of 2023. For instance, while Beam Therapeutics and Ginkgo Bioworks lost over 21% this year, Verve Therapeutics stock declined over 29% in the period.
儘管所有這些股票在過去一個月都錄得了負回報，但自 2023 年初以來，一些股票已顯著下降。例如，儘管束治療和銀杏生物製品今年損失了 21％，但神韻治療藥物的股票在此期間下降了 29％ 以上。
Some of these companies witnessed important developments over the last few weeks. For instance, CRISPR Therapeutics and $Vertex Pharmaceuticals (VRTX.US)$ announced the completion of the rolling of Biologics License Applications to the Food and Drug Administration for the investigational treatment exagamglogene autotemcel for sickle cell disease and transfusion-dependent beta thalassemia.
其中一些公司目睹了過去幾週的重要發展。例如，CRISPR 治療學和 $福泰製藥 (VRTX.US)$ 宣布完成了生物製劑許可證申請的滾動 美國食品藥物管理局 用於用於鐮狀細胞疾病和輸血依賴性 β 地中海貧血的研究治療自節膠。
Ginkgo Bioworks announced the acquisition of StrideBio's adeno-associated virus capsid discovery and engineering platform assets.
銀杏生物公司宣布收購 斯特里迪比奥 腺相關病毒機殼發現和工程平台資產。
Major Buy: ARK also bought over 147,000 shares of $Coinbase (COIN.US)$ valued at over $8.9 million based on Wednesday's closing price.
主要購買: 方舟還買了超過 14 萬股 $Coinbase (COIN.US)$ 根據星期三的收市價，價值超過 890 萬美元。
